Business Context and Reporting Period
Company: Nephros, Inc. (NEPH)
Filing Type: Form 8-K (Current Report)
Date of Report: November 21, 2025
Event: Entry into a new Material Definitive Agreement and termination of a prior agreement.
Key Financial Metrics and Obligations
This filing does not report historical revenue, profit, cash flow, or liquidity metrics. It discloses future contractual purchase obligations under a new supply agreement:
- Minimum Annual Aggregate Purchases (EUR):
- 2026: €4,976,000
- 2027: €5,349,000
- 2028: €5,750,000
- 2029: €6,000,000
- 2030: €6,300,000
- Counterparty: Medica S.p.A. (Italy-based manufacturer)
- Technology: Medisulfone ultrafiltration technology combined with Nephros filtration products.
Material Changes Versus Prior Period
The Company terminated a prior License and Supply Agreement dated December 11, 2023, and replaced it with the new agreement effective November 21, 2025. The new agreement establishes a five-year term through December 31, 2030, with escalating minimum purchase commitments.
Guidance, Outlook, and Contractual Terms
Agreement Structure:
- Exclusive License: Medica grants Nephros an exclusive license to market and sell the Products in the defined Territory. Nephros grants Medica an exclusive license to manufacture the Products.
- Term: Effective through December 31, 2030.
- Termination Rights:
- Nephros: May terminate for convenience with 90 days' prior written notice.
- Medica: May terminate if Nephros fails to cure a monetary default within 30 days of notice.
- Both Parties: May terminate for material breach (uncured) or specified insolvency events.
Management Commentary/Risks: The filing notes that the agreement contains customary representations, warranties, and indemnification obligations. The full text of the agreement will be filed as an exhibit to the Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Investor Verification Checklist
- Verify the exact definition of the "Territory" for the exclusive marketing rights in the full agreement text.
- Confirm the currency exchange rate assumptions for the EUR-denominated purchase obligations against the USD.
- Review the specific "monetary default" thresholds that could trigger termination by Medica.
- Assess the impact of the escalating minimum purchase commitments on future cash flow requirements.
- Check for any financial covenants or performance milestones not detailed in this summary.